Novotech Selected as CRO for Karyopharm’s COVID-19 Clinical Study

SYDNEY, Apr 29, 2020 – (ACN Newswire) – The Asia-Pacific's largest specialist biotech CRO Novotech has been engaged for a Phase 2 COVID-19 study by biotech sponsor Karyopharm Therapeutics Inc.





The Phase 2 randomized, open-label, multicenter study will evaluate the activity and safety of two regimens of low dose oral selinexor in patients with moderate or severe COVID-19 (NCT04355676). This is the second selinexor study in COVID-19 being initiated by Karyopharm and is expected to enroll 80 patients.

Novotech will manage the Asia-Pacific region for the study, which will include several sites in Australia and Malaysia.

XPOVIO(R) (selinexor), was approved by the U.S. FDA in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Karyopharm Therapeutics Chief Development Officer Ran Frenkel said:

"We have quickly mobilized our team to activate clinical trial sites globally and we are pleased to be working with Novotech on this important initiative. Novotech was appointed for their local regulatory and site knowledge, extensive infectious disease clinical research experience, and outstanding track-record in the Asia-Pacific region".

Novotech Chief Executive Officer Dr. John Moller said:

"Novotech is well positioned to partner with Karyopharm on this drug trial and we look forward to this collaboration. Novotech has exceptional relationships with sites and KOLs throughout the region, and we have processes in place to accelerate COVID-19 trials. The regulatory authorities and ethics committees in the region are fast tracking review processes, and sites have adapted quickly to the new environment."

Demand for clinical research in the Asia-Pacific is on the rise. The number of clinical trials initiated by biotechnology companies in Asia-Pacific since the beginning of March is about 10% higher than in the United States according to GlobalData.

About Novotech – https://novotech-cro.com

Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in Asia-Pacific. Novotech has been instrumental in the success of over a thousand Phase I – IV clinical trials for biotechnology companies. Novotech was established in 1996, with offices in 11 locations across the region, and site partnerships with major health institutions.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.

Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media contact:
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO(R) (selinexor), received accelerated approval from the U.S. FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. A supplemental New Drug Application was recently accepted by the FDA seeking accelerated approval for selinexor as a new treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Visit www.karyopharm.com.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Vingroup Completed Manufacturing Two Models of Ventilators for COVID-19 Treatment

HANOI, VIETNAM, Apr 29, 2020 – (ACN Newswire) – After more than 3 weeks from announcement of its ventilator manufacture plan for Covid 19 treatment, Vingroup updated on April 28th, 2020 that it has completed the manufacture and is preparing to introduce to the market two invasive ventilator models with a significantly high localization rate: VFS-410 and VFS-510. With the strong support of ministries, agencies, health experts and the US-based Medtronic, Vingroup's ventilators VFS-410 and VFS-510 ensure international quality standards and long-term value for use even after Covid-19 treatment period.

VSmart VFS-410 and VFS-510 are two "made in Vietnam" invasive ventilators manufactured and completed entirely by the Vingroup ecosystem. Particularly, VSmart VFS-410 is a special upgrade of the first edition of VFS-310 ventilator developed by Vingroup engineers based on the original community-shared design by Massachusetts Institute of Technology (MIT); meanwhile VSmart VFS-510 subjects to technology transferred and improvement from U.S.-based Medtronic, the world's leading producer of breathing apparatus.

VSmart VFS-410 is an invasive ventilator with turbine technology that have the same features with to high-end portable invasive ventilators on the market (only discarding Continuous Positive Airway Pressure (CPAP) mode). Based on the simple design of non-invasive ventilator by MIT-based marketing research team, VFS-410 is modified by Vingroup engineers to become an invasive ventilator with turbine technology instead of automatic bag squeezer technology to ensure high accuracy. Besides, the ventilator is provided with sensors that monitor and give warning about maintaining oxygen levels, positive end-expiratory pressure, measure patient breathing, and self-adjust to synchronize with this breath. All operating principles, boards, mechanical components, software and designs of VSmart VFS-410 are designed, developed and manufactured at Vingroup in close consultation with the Ministry of Health, international experts and Vinmec doctors.

VSmart VFS-510 is an invasive ventilator based on the design of PB560 ventilator model manufactured by Medtronic (USA) which has been familiar to doctors in Vietnam for years. VFS-510 is compact, lightweight, and portable with 6 flexible breathing modes that can be used for both adult and pediatric patients who need invasive or noninvasive breathing support as directed by their physicians.

Vingroup has actively researched to adress the global scarcity of materials for ventilator production by self-producing or localizing up to 70% of its ventilator components including extremely important and modern components such as: blower, boards (PCBA controller, power, etc.,), keyboard, display, battery and case, etc. Furthermore, Vingroup also coordinate with Medtronic team to adjust the software to ensure that the features of the VFS-510 are completely equivalent to the Medtronic's original PB560 ventilator.

Mr. Markus Leitner – Director General of Vinfast Automobile R&D Institute 1 said that: "It is such a miracle. After just over 3 weeks of researching ventilators, Vinsmart and Vinfast engineers have succeeded in researching, improving and mastering ventilator manufacturing technology from scratch. It can be said that, only Vingroup can create favorable conditions and generate motivation as well as putting "pressure" on us to do this utopia."

Their international standard performance enable VFS-410 and VFS-510 to not only timely meet the immediate needs for Covid 19 treatment but also continue to be used effectively in intensive care unit (ICU) of medical facilities with long-term value and effectiveness.

VFS-410 and VFS-510 will continue to be tested by leading hospitals and experts in Vietnam and will be evaluated by the Medical Council of all levels to ensure compliance with pre-circulation regulations. It is expected that the first batch of ventilators will be available on the market on May 15th, 2020.

Upon reception of two ventilator models transferred by Vingroup for quality evaluation, Mr. Nguyen Minh Tuan, Director of Department of Medical Equipment and Health Works under the Ministry of Health said that the Ministry of Health highly appreciates the work efficiency and determination of Vingroup and other manufacturers in implementing the Prime Minister's direction on manufacturing ventilators. "So far, we can affirm that Vietnam has initially mastered ventilator manufacturing technology. The Ministry of Health will continue to accompany Vingroup and other manufacturers to develop products and facilitate early evaluation to put products into production, meeting the needs of society during Covid-19 control and prevention" – Mr. Nguyen Minh Tuan added.

Successful manufacturing "made in Vietnam" ventilators not only contributes to price stability (PB560 ventilator selling price in Vietnam is now over 250 million VND/unit); but also ensures its initiative while the outbreak of Covid-19 has not been controlled in many countries. This is also the goal pursued by Vingroup in its non-profit ventilator manufacturing plan for the community.

Reference information:
– The PB560 ventilator with its full name Puritan Bennett(TM) 560 has been licensed by the U.S. Food and Drug Administration (FDA) for selling in the US market on April 5th, 2020 as prescribed in "Appendix B: Authorized Ventilators, Ventilator Tubing Connectors, and Ventilator Accessories" to meet market demand during the rapid spread of Covid-19 pandemic.
– Puritan Bennett(TM) 560 is an upgraded edition of Puritan Bennett(TM) 540, which is an FDA-licensed device for circulation in the US from October 31st, 2008.

Media contact: info@vingroup.net

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Novotech COVID-19 Clinical Trial Clients Benefit from New Asia-Pacific Fast-Track Review Processes

SYDNEY, Apr 28, 2020 – (ACN Newswire) – Asia-Pacific's largest specialist biotech CRO Novotech said many countries in the region were now fast-tracking their COVID-19 clients' clinical trials with expedited review processes for treatment and vaccine candidates.





A Novotech Client COVID-19 trial was just approved in under 9 days in South Korea.

The South Korean Ministry of Food and Drug Safety (MFDS) has announced "GO-expedite" program where they are expediting the review process for COVID-19 treatment and vaccine trials with specific timelines.

Other countries are also fast-tracking COVID-19 trial reviews including:
— India: review/approval in 10 working days
— Thailand: review/approval in 15 working days
— Malaysia: review/approval in 20 working days

Novotech Executive Director, Asia Operations, Dr. Yooni Kim said she was pleased to see such a rapid response in the region to support vital research.

"We are seeing an increase in demand from biotechnology sponsors for studies in the Asia-Pacific region because of the speed and quality available here. This expedited review process will further support the race for COVID-19 treatments."

For the latest updates on the Asia-Pacific clinical trial landscape see our Data Bulletins (updated weekly).
View and download COVID-19 Data Bulletins here: https://novotech-cro.com/covid-19-notice

About Novotech – https://novotech-cro.com

Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in Asia-Pacific. Novotech has been instrumental in the success of over a thousand Phase I – IV clinical trials for biotechnology companies. Novotech was established in 1996, with offices in 11 locations across the region, and site partnerships with major health institutions.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.

Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media contact:
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

GeoMap Clinical Patient Recruitment Platform Now Guarantees Enrollment Numbers

SAN FRANCISCO, CA, Apr 28, 2020 – (ACN Newswire) – GeoMap Clinical, the award-winning digital patient recruitment platform, today announced a Patient Enrollment Guarantee, ideal for sponsors wanting guaranteed patient enrollment numbers. See https://tinyurl.com/yd75bxh8.





The GeoMap Platform is now offering guaranteed monthly enrollment targets for sponsors wanting to remove the risk of missing timelines due to slow or stalled enrollment. In addition, GeoMap Clinical doesn't require IRB or EC approval, so it can start recruiting in under 24 hours.

This modern approach to enrollment is 100% digital, and finds the right people via hundreds of health and wellness news and social channels including HuffPost, CNN, Facebook and Instagram, and even patient advocacy websites and community groups.

The GeoMap Platform finds, screens, and then sends patients direct to sites via encrypted email – and doesn't keep their information. GeoMap uses an advanced AI conversational speech or typing technology to determine eligibility – making it easy for young and old patients to find the right trials.

The GeoMap Platform recruits for clinical trials in North America, Latin America, Australia, New Zealand, China, South Korea, Singapore, Thailand, and the EU.

The company said:

"The Patient Enrollment Guarantee is a response to client demand. Sponsors wanted a risk-share guaranteed approach from us and we have delivered: A new service specifically for tough to recruit studies or trials that have stalled and need a rescue strategy. For trial rescue clients, this is particularly attractive because it starts recruiting in under 24 hours."

GeoMap uses advanced algorithms and AI to find the right patients, and screened patient numbers can be viewed on the private Dashboard so sponsors can see exactly what is happening 24 x 7. This guarantee is unique in the patient recruitment sector which typically uses databases to find people then charges per referral.

"Our success is based on our powerful patient finder algorithms as well as our rigorous screener that only allows highly eligible people to connect through to sites. GeoMap is also ideal for pre-recruitment for studies on temporary hold or those about to start."

The GeoMap Platform is a 3-step process:

1. Find the right patients online using advanced algorithms across country specific social and news media, video and online search
2. Screen them using the Proprietary AI Patient Screener Funnel of more than 300+ possible questions
3. Connect them to sites via direct secure encrypted email to the study coordinator/s for a phone call.

The Platform has strict verification and email encryption so PHI is managed in accordance with state and country regulatory guidelines.

For more information and pricing please click here: https://www.geomapclinical.com/fixed-guarantee/

About GeoMap Clinical by TrialWire

The GeoMap Clinical Platform is the world's most advanced geo-location/targeting and AI platform powered by specialist algorithms that find and screen the right people living or working near sites. The GeoMap Platform recruits and screens patients online. Advanced algorithms find the right patients via news websites, social media, health and wellness websites and more, and connects eligible people with sites via encrypted email.

The Platform is a sophisticated location and health profile search service that sends only highly eligible people to their nearest site. It is designed to end pain points across the clinical trials sector, saving time and money at every stage, while ensuring patient privacy and regulatory compliance. GeoMap Clinical Platform is not a database builder. Patient ID is redacted instantly and the focus is instead on finding only motivated patients to support enrollment and retention.

For a briefing please click here: https://www.geomapclinical.com/fixed-guarantee/

Media Contact
Chris Thompson
team@dmgpr.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)

SHANGHAI, Apr 27, 2020 – (ACN Newswire) – Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112.

HMM0112 is a Phase I trial conducted in the United States in Type 2 Diabetes (T2D) patients with insufficiently controlled blood glucose levels while on metformin, DPP-4 inhibitors or SGLT-2 inhibitors, alone or in combination treatment. The principal purpose of HMM0112 is to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of dorzagliatin and empagliflozin (a SGLT-2 inhibitor) as either monotherapy or combination therapy. The PK results demonstrated no impact of dorzagliatin (75 mg BID) and empagliflozin (25 mg QD) on their respective PK properties under co-administration, supporting their combination use in the clinical setting, while the PD results demonstrated a clear synergistic effect in efficacy under combination therapy. Following OGTT, the combination treatment achieved significantly enhanced glucose lowering effect (AUEC: 279 h.mg/dL) over empagliflozin (AUEC: 452 h.mg/dL, P<0.01) or dorzagliatin (AUEC: 364 h.mg/dL, P<0.05) monotherapy. Moreover, significantly increased C-peptide secretion was also observed for the combination treatment over empagliflozin monotherapy. These results support the development of a combination therapy of dorzagliatin with empagliflozin, which will provide improved benefits and better solutions to T2D patients.

"SGLT-2 inhibitors are a relatively newer class of oral medications for the treatment of T2D patients, in addition to the blood sugar control, they were found to have the effect to lower blood pressure and reduce body weight. Their global sales in 2019 were approximately 6 billion US dollars," said Dr. Li Chen, Chief Executive Officer of Hua Medicine, "The positive results of HMM0112 indicate that dorzagliatin add-on to SGLT-2 inhibitors enhanced the blood sugar control for T2D patients thereby expanding the applicable patient population, and also suggest a synergistic effect of recovering pancreatic islet function. This successful outcome advances our mission to offer dorzagliatin as either monotherapy or in combination with the currently approved top-selling oral anti-diabetic drugs. Currently, we have demonstrated similar positive results of dorzagliatin in combination with sitagliptin (a DPP-4 inhibitor and top-selling oral anti-diabetic drug in the world) and metformin (the global first-line oral anti-diabetic drug). In this fashion, we are aiming to provide a brand new treatment for T2D patients to prevent or delay occurrence of the diabetes and its complications through dorzagliatin monotherapy or in combination with currently available diabetes therapies."

In November 2019, Hua Medicine announced that the Phase III monotherapy trial (HMM0301) of dorzagliatin in drug naive T2D patients achieved its 24-week primary efficacy endpoint. The Company plans to announce the top-line 52-week key results for the monotherapy trial by no later than the third quarter of 2020. The 24-week patient visit for HMM0302, another Phase III combination trial of dorzagliatin add-on to metformin, was also completed. The Company plans to announce the top-line 24-week key results for the combination with metformin trial (HMM0302) by no later than the third quarter of 2020, and top-line 52-week key results by year-end 2020. In January 2020, the Company also announced the desirable results of dorzagliatin combination with sitagliptin Phase I trial (HMM0111), confirming the clinical advantages and potential synergies of dorzagliatin in combination with sitagliptin (a DPP-4 inhibitor). Meanwhile, the positive results of another Phase I trial (HMM0110) revealed the potential to use dorzagliatin in T2D patients with late stage chronic kidney disease.

About Dorzagliatin

Dorzagliatin is a first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 Diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 Diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.

About Hua Medicine

Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.

For more information

Hua Medicine
Website: www.huamedicine.com

Investors
Email: ir@huamedicine.com

Media
Email: pr@huamedicine.com



Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Impact Biomedical’s Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts

SINGAPORE, Apr 24, 2020 – (ACN Newswire) – SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). Following encouraging COVID-19 testing results, the groundbreaking technology was independently valued by recognized intellectual property valuation and licensing firm Destum Partners, known globally for its high level of expertise and capability in independently valuing and licensing pharmaceutical technology. The commercial assessment includes: 3F Biofragrance – a key component of the Open Air Defense Initiative, Equivir – an OTC medication with broad antiviral activity, and Linebacker – a broad-spectrum universal therapeutic. Continuing development of the COVID-19 research program is underway.

This research is part of a multi-year pandemic research program conducted by Impact Biomedical's research partner, GRDG Sciences, LLC ("GRDG"), which covers a wide range of solutions to global health issues to adhere to the principles and initiatives established by Project Bioshield and the Biomedical Advanced Research and Development Authority (BARDA). All three compounds were tested against a rigorous in vitro respiratory virus panel by GRDG, who utilized the non-clinical and pre-clinical services program offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Previous antimicrobial research was conducted at multiple independent laboratories. The technology consists of:

– 3F Antiviral Biofragrance – 3F Antiviral Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and ports of entry. The concept is rather than quarantine people from the virus, quarantine the virus from people. 3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET. 3F Mosquito uses other receptor modalities than traditional mosquito repellents to effectively blind humans to mosquitoes. The Open Air Defense Initiative was created as a solution for Event 201, a pandemic exercise conducted in 2019 by the Johns Hopkins Center for Health Security, the World Economic Forum and the Bill and Melinda Gates Foundation. Event 201 highlighted areas where public/private partnerships are vital to respond to a severe pandemic. 3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.

– Equivir – Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies. Equivir is a patented OTC medication that has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.

– Linebacker – Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency (DARPA). Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson's, multiple histotypes of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and COVID-19.

– Laetose – Laetose is a reduced calorie low glycemic sugar replacement created to address the rising global problem of metabolic disorders and associated conditions.

Previous research identified the Angiotensin converting enzyme 2 ("ACE2") as the host receptor for SARS-CoV-2, the virus causing the COVID-19 pandemic. Molecular docking conducted by GRDG indicated that Linebacker and Equivir cause a conformational change and modulate the ACE-2 receptor and block three integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease on the ACE-2 receptor.

"This professional valuation further validates our technologies, allowing us to move to the next step of engaging in further collaborations to bring things up to speed" said Mr Chan Heng Fai, Executive Chairman of SeD.

GRDG's Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said, "the multiple strategies developed by GRDG to fight global healthcare issues including the recent COVID-19 pandemic are important advances in science to potentially save many lives."

Also advising GRDG is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive/Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer. Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, "GRDG's multi-prong strategy to develop and validate different technologies for threats to health is a positive step forward to address many unmet medical needs including the application of evolving novel interventions to address the current Coronavirus pandemic."

Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, "We are proud of the Impact Biomedical research team and the successful accomplishment of a 5 year research and development project focused on the identification and proving of viable biodefense countermeasures as outlined in the Pandemic and All Hazards Preparedness Act established in 2006.

"Moving ahead we are looking forward to another series of research focused on developing global viral mitigation and control technologies for scenarios such as the current COVID-19 outbreak, the development of novel antiviral therapeutics, as well as addressing solutions for the impending 'patent cliff' crisis expected in 2024.

"Impact Biomedical and its research partner Global Research and Discovery Group Sciences will work with leading global policy makers to establish specially created research teams focused exclusively on 'difficult to achieve' or nearly impossible projects utilizing lessons learned from our previous projects."

Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.

About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by drug discovery research scientist, Daryl Thompson. For more information, please visit: http://www.globalrdg.com.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market

HONG KONG, Apr 24, 2020 – (ACN Newswire) – Though the COVID-19 pandemic has blanketed the capital market in 2020, biotech stocks have stood out. Pharmaceutical stocks have become popular ones in the capital market as people pay more attention to health due to the pandemic. Many biotech companies have planned for IPO in Hong Kong this year. Akeso Inc. (the "Company", 9926.HK), a leading biopharmaceutical company in China, has been listed on the Stock Exchange of Hong Kong (HKEX) today. Akeso, Inc. (9926.HK) has attracted much market attention since its IPO. It is said that Akeso locked up a record about HK$165 billion, possibly crowning it the king of frozen capital this year. It is reported that before the listing, Akeso introduced nine cornerstone investors who subscribed for USD163 million of shares in total. Fidelity Investment, who provides world-class, long-term investment solutions, and Lake Bleu Capital, who is specialising in healthcare investment, led the cornerstone investment, while international reputable investment funds and healthcare specialists like OrbiMed Funds, Boyu Capital, and Hudson Bay participated in it, which has constituted the strongest group of investors in recent years. Akeso was listed on the Hong Kong Stock Exchange today.

Efficient R&D Platform and Strong R&D Strength

The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.

The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.

Prominent Advantages of Core Products, Favored by the Capital Market

The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.

The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.

The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.

AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.

Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.



Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Shinsung TK Participates in ‘Arab Health 2020’, the Largest Medical Device Exhibition in the Middle East

GWANGJU, KOREA, Apr 24, 2020 – (ACN Newswire) – Shinsung TK Co., Ltd., a company specializing in IoT-based healthcare systems, participated in the 45th Dubai International Medical Equipment Exhibition (Arab Health 2020) at the Dubai World Trade Center, from January 27 to 30 this year. Arab Health, representing more than 159 countries, is an international medical exhibition that provides businesses with various opportunities to reach new and potential customers from around the world.





During the exhibition, Shinsung TK held meetings with 45 companies at its booth, identifying the needs of investors and understanding the market of each country. Not only was the technological excellence of its IoT-based iRINGER IV Infusion Monitoring System universally recognized, but Shinsung TK affirmed its potential as a partner as well, having collaborated with various companies around the world and playing a major role in technology development.

iRINGER, a smart Infusion Monitoring System, automatically calculates the amount and speed (cc/hr) of the infusion, and uses wireless technology to inform nurses and medical personnel outside the hospital ward via smartphone or PC web. It also provides an alarm (sound and vibration) through a smart call (automatic transmission) when an anomaly occurs.

Shinsung TK has been participating in the health care exhibition annually since 2016, promoting its product technology continuously to establish its position in the overseas medical market. Recently, the use of iRINGER has increased as issues of non-face-to-face treatment following the coronavirus became significant.

Eunseop Lim, the CEO of Shinsung TK, said "Based on our IoT remote infusion monitoring technology, which is the result of continuous technology investment and innovation, the company plans to expand its smart healthcare platform technology in the future to measures not only the infusion, but also the patient's body temperature and pulse, temperature and humidity, and urine volume."

Shinsung TK signed an MOU agreement with the Malaysian company LKL in 2019. It will participate in the Medicine 4.0 conference with LKL at Malaysia's Matrade Convention Center for two days from August 8th – 9th 2020 to showcase its technology.

Media contact
SHINSUNG TK Co., Ltd.
Contact: Eun Suab Lim
Email: sstop77@shinsungtk.com
Phone: +82-62-972-0629
Website: http://shinsungtk.com/en/


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Azabu Insights: Mask Usage in Tokyo Reaches Ninety-Seven Percent And Other Reasons Asian Countries Are Winning Against Coronavirus

TOKYO, Apr 23, 2020 – (ACN Newswire) – A group of consultants based in Azabu Juban have been following the coronavirus, spread, and response around the world. We have been tracking mask usage in Tokyo over the last months and readers had asked us to update these. In addition we wanted to take a look at global responses to the coronavirus pandemic to find keys for moving forwards.



[Image #1] European/Asian Countries by Cases and Deaths Per Population (April 21, 2020)


[Image #2] Percent of People Wearing Masks – Azabu Jyuban, Tokyo (Mar. 13, Apr. 2, Apr. 17)


[Image #3] Decrease in Ridership from April 2 to April 17, Azabu Jyuban



Even as cases have grown in Japan and Singapore, we find it remarkable how well Asia has fared and how effective their measures have been overall, taken in a global context. In this piece, we will therefore update mask usage numbers, compare global outbreak statistics, and look at some of the measures large and small that seem to have been effective in Asian countries so far.

As one reader commented, "we may need to start to think of dealing with the coronavirus not as a sprint, but as a marathon." In this light we find it instructive to look back at some of the successes Asia countries have had, so far.

Response from Asia

As people stay focused on their own country they often forget that in a wider perspective solutions have been very helpful. As shown in the table, countries like Taiwan, Korea and Japan have been able to keep death rates much lower than those of Italy, Spain, and the United States. Death rates in the Asian countries come in at less .5 per 100,000, whereas in many European countries they are more than one hundred times that amount.

[Image #1] European/Asian Countries by Cases and Deaths Per Population (April 21, 2020)

Masks in Tokyo Up Thirteen Percent

As the Japanese government and citizens get ever more vigilant about controlling the coronavirus, we have found that mask wearing has become ubiquitous in Japan. We updated our survey for a third time, on April 17th. This time we found ninety-seven percent of people wearing masks.

This is up from eighty-six percent on April 2nd (thirteen days ago), and sixty-four percent March 13 (thirty-five days ago), an increase of thirteen percent.

In this survey, again, women were more likely to wear masks, though only barely. Ninety-eight percent of women wore masks and ninety-seven percent of men wore them. See the charts below for the changes over time.

[Image #2] Percent of People Wearing Masks – Azabu Jyuban, Tokyo (Mar. 13, Apr. 2, Apr. 17)

In addition we found the more proactive approach towards beating the virus to have had a significant effect on ridership as well. Said a Sawayaka Shinyou Kinkou bank employee who commutes daily, "oh there are definitely less people; now people even open a seat next to each other on the train, rather than crowding in like they used to." Our data backed up her inference, with ridership down forty-nine percent on April 17th compared to April 2nd.

[Image #3] Decrease in Ridership from April 2 to April 17, Azabu Jyuban

NOTE: All data collected at identical times during a ninety minute period during rush hour. All days were clear, temperate days. Average temperatures on the three days were 14, 15 and 12 degrees celsius and 57, 59, and 54 degrees fahrenheit. The temperature came down slightly.

Getting Ready for the Long Haul – Asia Strategies Working

Following along with the goal of thinking of coronavirus as a marathon, we wanted to look for other examples of success in containing the virus that might be applicable to other countries in Asia or the West.

We find the successes in Taiwan, Japan, Singapore, China, South Korea, and Thailand to be frankly. All of these countries have kept death numbers very low compared to western countries. They have done this largely while still keeping at least a portion of the population at work and pushing the economies forwards.

We have identified important learnings from each country:

Lessons from China

China perhaps had the most significant early success. We noted three of the most significant measures.

1. It quarantined Wuhan from the rest of China on January 23rd, just before Chinese New Year, China's largest holiday period for both in-country and international travel. This allowed it to largely contain the spread and it allowed them to provide more healthcare workers and supplies to Wuhan.

2. As a part of this exercise, it also forced an internal quarantine in Hubei, shutting down non-essential businesses and locked down 11 million people in Wuhan and (the following day) more than 57 million people in other cities.

3. Third, it built two coronavirus hospitals (February 3rd). This led to a rapid drop off in deaths from the worst day of 150 deaths on February 23rd level down to less than 10 per day in only 19 days. We find these last hospitals to have been very important given the amount of in-hospital spread previously noted. In one study 42% of cases in Wuhan had previously been spread within the hospital.

We found that the coronavirus only hospitals that were built were truly amazing. However, subsequently in the UK a 4,000 bed hospital was built in the ExCeL Center in nine days and The United States's Corp of Army Engineers created seventeen hospitals with 15,500 beds in about a week. We believe that building these hospitals was so important because it has become clear that up to forty percent of spread has typically been inside hospitals and this is killing many at risk people.

Lessons from Taiwan

Taiwan has perhaps been the most successful, with only 422 cases and just 6 deaths. It was the most proactive, testing people for temperature on flights before it had even had a one case recorded.

It was also very proactive with other measures. For instance on January 29 the Taiwan Premier took steps to guarantee the supply of masks including releasing 23 million mask into the market and banning their export. By April 1st, Taiwan's successful measures led to them approaching their target of producing 15 million masks daily and announced it was donating 10 million masks to health workers outside of Taiwan.

The masks seem to have shown their efficacy again. We think it is a combination of catching some droplets, while also keeping people vigilant about isolating as much as possible even while in public. The relative success of Taiwan has been so high that they were able to open Taiwan baseball (albeit with no fans) a week ago.

Lesson from South Korea

South Korea, as most know, took to mass testing and a number high tech tracking measures so as to track the one major cluster that emanated out from an outbreak in a church in Daegu.

More than seven-thousand cases were confirmed in less than three weeks, but the death rate remained low.

Their attention to tracking and quarantining people affected by an outbreak was successful in controlling the spread with only .5 deaths per 100,000 population as of the writing of this article.

Hong Kong and Singapore

Despite its proximity to China and role as international transit hub, Hong Kong has successfully minimized its coronavirus impact with 1,026 confirmed cases and just 4 deaths. It acted quickly in late January to shut a number of border crossings, significantly reducing travel to and from China and implementing work from home orders. It has since tightened travel restrictions and shut schools.

Singapore immediately set up a multi-ministerial committee on January 24th, the day after the first confirmed case, to manage the pandemic.

Singapore has implemented strict cluster tracing, put in place airport temperature checks and set up holiday chalets to use as quarantine centres. Hong Kong has managed only .5 deaths per 100,000 population and Singapore has achieved only .2 deaths per 100,000 population.

Lessons from Japan

Japan has seen a spike in cases and deaths recently and has been criticized for low numbers of tests. However, like Singapore Japan has maintained death rates at .2 per 100,000 people. Again, this is compared to European countries such as Spain with 45 per 100,000 people (225 times the number on a per person basis). Many of its measures have proven effective so far, including:
1. Publicizing the most dangerous outbreak areas
2. Carefully tracking early clusters
3. Keeping coronavirus patients largely out of hospitals and nursing homes
4. Setting targets for reduction interactions (now set at eighty percent).

From the get go Japanese media daily reported the exact places where outbreaks were occurring: first taxi cabs, then karaoke bars, then live music events. These gave the populous clues of where to avoid and eventually a focus for what activities to shut down first. The Japanese citizens were largely attuned to understanding these dangerous activites and taking responsibility to avoid them as much as possible. Later the government was able to successfully "request" that many of these venues temporarily shut down. Again, with no law enforcement capability they achieved the limitations with the cooperation of business owners.

Secondly, Japan effectively kept coronavirus cases away from hospitals. As Azabu Insights has noted before, this is very important because seventy-three percent of people in hospitals are over age sixty-five and very vulnerable.

Lastly, their targeting of a specific target for reduction of interactions has significantly slowed the spread. Japan showed, as had Taiwan and Korea that a semblance of work can continue while still drastically slowing the spread of the disease.

The Effect of BCG Vaccination

Beyond the proactive nature of the Asian communities with masks, hand washing, polite social distancing, school closure and the like, we think that many parts of Asia have likely benefited from the protection of the BCG Vaccines. The BCG Vaccine, which was intended to protect from Tuberculosis seems to have some protectiveness against coronavirus.

The BCG vaccine has been used extensively in Japan, South Korea, Thailand, Taiwan, Singapore, and Hong Kong. It is not used in countries such as Italy, Spain, and the United States, which have had some of the worst outbreaks.

Hopes and Recommendations for the Future

For round one of the coronavirus outbreak, many of the Asian countries have fared very well compared to other parts of the world. But coronavirus may well be a marathon and not a sprint.

We hope and recommend that they will adopt the following policies going forwards:

1. Continue to keep testing in locations separate from hospitals to keep the virus from spreading in hospitals.
2. Build multiple 2-4,000 bed "coronavirus only" hospitals, staffed by young, low-risk doctors and nurses. This will allow the healthcare system to continue to treat the rest of society well.
3. Increase testing at targeted areas, including all people that enter an aged care facility (some twenty percent of deaths in USA are at aged care facilities)
4. Involve the military/self defense forces in helping to create hospital capacity and to safely transport coronavirus patients
5. Adopt the new secure outbreak tracking technologies offered by some of the tech companies that can allow us to track clusters even as populations grow. This will allow us to track clusters effectively.
6. Continue to be strategic in keeping the right things closed and targeting a reduced number of interactions. This necessarily requires finding funding to support small businesses.
7. Move to vaccinate more populations with BCG, including non-Japanese who request them.
8. We hope that individuals will remain vigilant as we wait for more good news about treatments and a potential vaccination. Wearing masks has some effect, making the move to more indoor home activities helps even more.

As Europe and America take baby steps towards loosening stay at home orders, we hope they will also learn from some of the relative successes of the Asian countries mentioned above. Of course as we continue on this journey, Asia probably has lessons to learn from the USA and Europe as well.

We would like to hear your opinions at info@azabuinsights.com

About Azabu Insights

Azabu Insights is a boutique strategic consulting company based in Azabu Juban, Tokyo, Japan. Our teams work collaboratively with clients to build strategies that lead to positive change. Our multilingual team members have top tier academic backgrounds and deep industry experience that we leverage to provide first class, fully engaged, strategic consulting. Core specializations include life sciences, finance, electronics, automotive, aerospace and other industries. For more information contact: info@azabuinsights.com.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Blockchain Holdings Enters into Definitive Agreement for Acquisition of COVID-19 Quarantine Management Product TRACEsafe

TORTOLA, BRITISH VIRGIN ISLANDS / ACCESSWIRE, Apr 23, 2020 – (ACN Newswire) – Blockchain Holdings Ltd. ("Blockchain") (CSE:BCX) is pleased to announce that, further to its previous news release, it has executed a definitive agreement (the "Purchase Agreement") providing for the acquisition, through its wholly-owned subsidiary, Tracesafe Technologies Inc. ("Tracesafe Technologies Inc."), of the self-quarantine monitoring technology suite known collectively as "TRACEsafe" from WiSilica, Inc. ("WiSilica"). TRACEsafe is a global health product designed for deployment by governments and corporations as they fight the global COVID-19 pandemic.

TRACEsafe is an innovative suite of patent-protected health and safety products, including a bracelet with an embedded chip and related software to track the wearer's location. It was developed and deployed for maternity wards and senior citizen's housing and has now been transformed to help governments and health authorities manage and track those in COVID-19-related quarantine. It is expected that ongoing COVID-19 quarantines may be required over the next 12-24 months, pending development and widespread distribution of a vaccine. In addition, Blockchain believes TRACEsafe can function as a critical tool to help manage any future pandemics, including any resurgence of COVID-19, when added to a government's national health arsenal.

Already, initial deliveries of TRACEsafe disposable bracelets have been deployed and are in use by the Hong Kong government to manage and enforce their quarantine program for foreign visitors. TRACEsafe is expected to roll out in multiple countries over the coming weeks and months.

The Transaction

Pursuant to the Purchase Agreement, Tracesafe Technologies Inc. will acquire from WiSilica the "TRACEsafe" self-quarantine monitoring technology suite. Under the terms of the transaction, the consideration for the TRACEsafe assets will consist of a cash payment of USD$250,000, to be paid as a deposit which is refundable in certain circumstances, and 4,516,395 non-voting common shares in the capital of Tracesafe Technologies Inc. (the "Tracesafe Common Shares"), which, subject to certain voluntary conversion restrictions, are exchangeable for 4,516,395 common shares in the capital of Blockchain (the "BCX Common Shares").

In addition, WiSilica will receive an aggregate of 1,483,605 preferred shares in the capital of Tracesafe Technologies Inc., which may be converted into an aggregate of up to 19,286,865 Tracesafe Common Shares, upon satisfaction of three separate performance milestones relating to the commercialization of the TRACEsafe assets. Such Tracesafe Common Shares are, subject to certain voluntary conversion restrictions, exchangeable for an aggregate of up to 19,286,865 BCX Common Shares.

WiSilica has agreed that the conversion of Tracesafe Common Shares will be subject to certain voluntary conversion restrictions (effectively, voluntary resale restrictions on the BCX Common Shares they would otherwise receive) as follows: (a) in the first four (4) months, no Tracesafe Common Shares may be exchanged; (b) after such time until January 1, 2021, no more than 20% of the Tracesafe Common Shares may be exchanged; (c) after such time until the first anniversary of the date of issuance, no more than 66.67% of the Tracesafe Common Shares may be exchanged; (d) after such time until January 1, 2022, no more than 83.33% of the Tracesafe Common Shares may be exchanged; and (e) after January 1, 2022, all outstanding Tracesafe Common Shares may be exchanged.

The exchange of Tracesafe Common Shares may be settled, in the sole and absolute discretion of Tracesafe Technologies Inc. and Blockchain, by way of cash payment in lieu of the issuance of BCX Common Shares.

Dennis Kwan, the CTO of WiSilica, is expected to be appointed as CEO of Tracesafe Technologies Inc. on closing of the transaction to help continuity of ongoing operations and deployment of TRACEsafe technology to governments and the private sector around the world.

Completion of the transaction is subject to customary closing conditions, including, among other things, the negotiation and execution of certain ancillary agreements, the receipt of any third-party consents, and the receipt of approval from the Canadian Securities Exchange.

Executive Quotes

"The TRACEsafe technology represents the culmination of years of innovation in low-power wireless technology from WiSilica. With the support of Blockchain Holdings, we believe we can launch TRACEsafe into a new stage of growth and provide a critical tool to assist governments as they mitigate the spread of COVID-19 and also large corporations and organizations to protect employees' health as they re-open for business," explained Dennis Kwan, CEO of Tracesafe. "I couldn't be more excited to be a part of this cutting-edge opportunity to help combat COVID-19."

"The acquisition of TRACEsafe will further advance our technology and data aggregation business and highlight our role as a value-added investor in disruptive technology startups," remarked Wayne Lloyd, CEO of Blockchain.

About TRACEsafe

TRACEsafe is a proprietary self-quarantine management monitoring system which registers a user through a wrist tag. The tag can log time stamps and locations of the user through a single application used by both the user and administrators to a central monitoring system. TRACEsafe allows a user to declare once they have entered quarantine, and subsequently prompts periodic check-in acknowledgements. The application will alert administrators if the user fails to acknowledge a check-in, the tag is unreachable through the user's phone or if any tampering with the tag is suspected.

TRACEsafe was developed by WiSilica, a California-based private company in the business of creating intelligent Internet of Things (IoT) solutions to enable human centric lighting, real time tracking, intelligent wireless controls, and customized IoT Solutions. It helps customers manage space, energy, and gain access to insightful reports and dashboards.

About Blockchain Holdings

Blockchain provides investors and fund managers with unique insights into the growing ecosystem of crypto-assets. BCXdata.com captures and aggregates data from different blockchains for use and analysis with a clean and approachable API. With a portfolio of proprietary tools, Blockchain is giving users an institutional-grade analysis package that forms the basis for an extended suite of product offerings in the future.

None of the securities to be issued pursuant to the transaction have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued pursuant to the transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

For further information, please contact:
Wayne Lloyd, CEO
+1-604-629-9975
wayne@blockchainholdingsltd.com

Alan Tam, CFO
+1-604-377-7575
alantamca@gmail.com

This press release was prepared by management of Blockchain, which takes full responsibility for its contents. The Canadian Securities Exchange has in no way passed upon the merits of the proposed transaction and has neither approved or disapproved the contents of this press release.

Statements in this news release may contain forward-looking statements that are based on Blockchain's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to expectations regarding the TRACEsafe assets, future developments in respect of COVID-19, the appointment of Dennis Kwan to a leadership role with respect to the TRACEsafe assets, the completion of the transaction in accordance with the terms of the Purchase Agreement, the satisfaction of the closing conditions by the parties, and the expected benefits of the transaction. Although Blockchain believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Blockchain undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE: Blockchain Holdings Ltd.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com